largazole

an antiproliferative agent from Symploca; structure in first source

Networked: 27 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - largazole: 27
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - largazole: 27
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - largazole: 27
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - largazole: 27

Experts

1.	Luesch, Hendrik: 8 articles (08/2021 - 11/2010)
2.	Jiang, Sheng: 6 articles (01/2020 - 03/2010)
3.	Hong, Jiyong: 5 articles (01/2017 - 11/2010)
4.	Chen, Qi-Yin: 3 articles (08/2021 - 08/2014)
5.	Williams, Robert M: 3 articles (04/2015 - 08/2008)
6.	Al-Awadhi, Fatma H: 2 articles (01/2020 - 08/2014)
7.	Ratnayake, Ranjala: 2 articles (01/2020 - 01/2017)
8.	Salvador-Reyes, Lilibeth A: 2 articles (01/2020 - 03/2015)
9.	Zhou, Guang-Biao: 2 articles (01/2020 - 10/2013)
10.	Kim, Bumki: 2 articles (01/2017 - 08/2014)

Related Diseases

1.	Triple Negative Breast Neoplasms 03/07/2013 - "Further studies indicated that the glucocorticoid dexamethasone and the highly potent class I histone deacetylase (HDAC) inhibitor largazole cooperated to induce E-cadherin localization to the plasma membrane in triple-negative breast cancers, and to suppress cellular invasion in vitro. "
2.	Corneal Neovascularization 10/05/2014 - "In this study, we examined the effect of largazole, an inhibitor of class I HDACs, on inflammatory corneal angiogenesis. " 10/05/2014 - "In a mouse model of alkali-induced corneal neovascularization (CNV), topical application of largazole to the injured corneas attenuated CNV. " 10/05/2014 - "Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization."
3.	Pancreatic Neoplasms (Pancreatic Cancer) 04/01/2015 - "In vitro studies in colon, lung, and pancreatic cancer cell lines showed that pyridyl-substituted Largazole analogs had low-nanomolar/high-picomolar antiproliferative activity, and induced apoptosis and cell cycle arrest at concentrations equivalent to or lower than the parent compound Largazole. "
4.	Lung Neoplasms (Lung Cancer) 10/10/2013 - "Interestingly, largazole enhances the E2F1-HDAC1 binding affinity and induces a proteasomal degradation of E2F1, leading to suppression of E2F1 function in lung cancer but not normal bronchial epithelial cells. " 10/10/2013 - "Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells." 10/10/2013 - "Because E2F1 is overexpressed in lung cancer tumor samples, these data indicate that largazole is an E2F1-targeting cell cycle inhibitor, which bears therapeutic potentials for this malignant neoplasm. " 10/10/2013 - "In this study, we test the effects of a natural macrocyclic depsipeptide largazole on lung cancer cells and report that this compound potently inhibits the proliferation and clonogenic activity of lung cancer cells but not normal bronchial epithelial cells. "
5.	Liver Cirrhosis (Hepatic Cirrhosis) 04/01/2013 - "This study investigated the effects of largazole against liver fibrosis. " 04/01/2013 - "Our findings revealed a novel role of largazole in the treatment of liver fibrosis. " 04/01/2013 - "A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling."

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Depsipeptides
3.	Histone Deacetylases (Histone Deacetylase)
4.	Cadherins (E-Cadherin)
5.	Glucocorticoids
6.	Dexamethasone (Maxidex)
7.	Sulfhydryl Compounds (Thiols)
8.	Tyrosine (L-Tyrosine)
9.	romidepsin (FK228)
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics